keyword
MENU ▼
Read by QxMD icon Read
search

Risedronate

keyword
https://www.readbyqxmd.com/read/29329484/effects-of-teriparatide-compared-with-risedronate-on-the-risk-of-fractures-in-subgroups-of-postmenopausal-women-with-severe-osteoporosis-the-vero-trial
#1
Piet Geusens, Fernando Marin, David L Kendler, Luis A Russo, Cristiano A F Zerbini, Salvatore Minisola, Jean Jacques Body, Eric Lespessailles, Susan L Greenspan, Alicia Bagur, Jan J Stepan, Péter Lakatos, Enrique Casado, Rüdiger Moericke, Pedro López-Romero, Astrid Fahrleitner-Pammer
The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who had at least 2 moderate or 1 severe baseline vertebral fractures (VFx), and BMD T-score ≤-1.5. Patients were treated with either s.c. daily teriparatide 20 μg or oral weekly risedronate 35 mg. As previously reported, the risk of new VFx and clinical fractures (a composite of clinical VFx and non vertebral fragility fractures [NVFFx]) was statistically significantly reduced with teriparatide compared with risedronate...
January 12, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29236162/bisphosphonates-prevent-age-related-weight-loss-in-japanese-postmenopausal-women
#2
Tomohiko Urano, Masataka Shiraki, Tatsuhiko Kuroda, Shiro Tanaka, Fumihiko Urano, Kazuhiro Uenishi, Satoshi Inoue
Decline of body weight with aging is a major risk factor for frailty, osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. Recently, we have shown that 5-year treatment with raloxifene prevented age-related weight loss, suggesting some other drugs for osteoporosis may also prevent a decrease in body weight with aging. The present study aimed to identify the relationship between bisphosphonate treatment and body composition markers. We measured bone mineral density (BMD), body composition, and bone remodeling markers in 551 Japanese postmenopausal women with bisphosphonate treatment, which included risedronate or alendronate treatment (BP-treatment group; N = 193) and without treatment by any osteoporosis drug (no-treatment group; N = 358) for 4-7 years (mean observation periods; 5...
December 13, 2017: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29227547/a-network-meta-analysis-on-the-short-term-efficacy-and-adverse-events-of-different-anti-osteoporosis-drugs-for-the-treatment-of-postmenopausal-osteoporosis
#3
Gui-Feng Liu, Zong-Qiang Wang, Lin Liu, Bu-Tian Zhang, Ying-Ying Miao, Shao-Nan Yu
A network meta-analysis was conducted to compare the short-term efficacy and adverse events of different drugs for the treatment of postmenopausal osteoporosis (PMO), providing a more effective treatment for PMO. We initially searched through various databases like PubMed, Cochrane Library and EMBASE from inception till October 2016. All randomized controlled trials (RCTs) of drugs for the treatment of PMO were included for direct and indirect comparison. A combination of direct and indirect evidence of different inhibitors of antidiabetic drugs for treatment of PMO were considered for calculating the weighted mean difference (WMD) value or odd ratio (OR) value and to draw surface under the cumulative ranking (SUCRA) curves...
December 11, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29222056/are-bisphosphonates-efficacious-in-knee-osteoarthritis-a-meta-analysis-of-randomized-controlled-trials
#4
E E Vaysbrot, M C Osani, M-C Musetti, T E McAlindon, R R Bannuru
OBJECTIVE: To clarify the effects of bisphosphonates in knee osteoarthritis (OA) using an up-to-date meta-analysis of randomized controlled trials (RCTs). DESIGN: The protocol is registered in PROSPERO (CRD42017073449). We searched MEDLINE, EMBASE, Google Scholar, Web of Science, and Cochrane Database from inception until August 2017. We included only RCTs comparing any bisphosphonates vs placebo in knee OA patients and reporting validated pain and function scales, radiographic progression, and adverse events (AEs) outcomes...
December 6, 2017: Osteoarthritis and Cartilage
https://www.readbyqxmd.com/read/29214795/retraction-paper-comparison-of-the-effect-of-vitamin-k2-and-risedronate-on-trabecular-bone-in-glucocorticoid-treated-rats-a-bone-histomorphometry-study-by-iwamoto-j-et-al-yonsei-med-j-2009-50-2-189-194
#5
https://www.readbyqxmd.com/read/29214023/assessment-and-clinical-management-of-bone-disease-in-adults-with-eating-disorders-a-review
#6
REVIEW
Anne Drabkin, Micol S Rothman, Elizabeth Wassenaar, Margherita Mascolo, Philip S Mehler
Aim: To review current medical literature regarding the causes and clinical management options for low bone mineral density (BMD) in adult patients with eating disorders. Background: Low bone mineral density is a common complication of eating disorders with potentially lifelong debilitating consequences. Definitive, rigorous guidelines for screening, prevention and management are lacking. This article intends to provide a review of the literature to date and current options for prevention and treatment...
2017: Journal of Eating Disorders
https://www.readbyqxmd.com/read/29208888/polyarthritis-is-a-rare-manifestation-of-pachydermoperiostosis-a-case-report
#7
M F Ahmmed, M N Shazzad, S Ferdous, A K Azad, S A Haq
Pachydermoperiostosis or primary hypertrophic osteoarthropathy, also known as Touraine-Solente-Gole syndrome, is a rare process, frequently inherited. In its complete form it is characterized by pachydermia (thickening of the skin), skeletal changes (periostosis) and acropachia (digital clubbing). Diagnosis can be made considering the typical clinical features and the histological feature. We report a patient of 25-year old man presented with joint pain involving in multiple joints for last 7 years and progressive enlargement of his hands and feet with profuse sweating of palms and soles for last 4 years...
October 2017: Mymensingh Medical Journal: MMJ
https://www.readbyqxmd.com/read/29207226/-the-treatment-of-the-patient-presenting-with-chronic-kidney-disease-ckd-and-fragility-fractures
#8
REVIEW
Andrea Giusti, Maria Fusaro
Fragility fractures occur in all stages of chronic kidney disease (CKD) due to low bone mineral density and poor bone quality (namely osteoporosis), as well as in CKD-mineral and bone disorders (CKD-MBD). As in postmenopausal women and older adults, the prompt identification of CKD subjects with a history of fragility fractures is crucial in order to implement strategies to reduce the risk of new fragility fractures and their consequences. The treatment of severe osteoporosis for patients with stages 1-3 CKD should not differ from patients without CKD, while clinical decisions and pharmacological treatments in subjects with stages 4-5/5D CKD differ greatly, being more tricky and challenging...
December 5, 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/29196083/the-good-and-the-bad-about-the-2017-american-college-of-physicians-osteoporosis-guidelines
#9
Violet Lagari, Tara Gavcovich, Silvina Levis
PURPOSE: The American College of Physicians (ACP) published a set of guidelines on how to prevent fractures in men and women with low bone density or osteoporosis. As the population ages, the overall risk of fractures increases, thus burdening the health care system. These guidelines review current evidence for osteoporosis management, providing an update to the previous 2008 ACP's guidelines. METHODS: The ACP put forth 6 recommendations addressing the complexities in osteoporosis management based on evidence available through October 2016 with a focus on bisphosphonates, calcium, vitamin D, and estrogen...
November 28, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29192423/bisphosphonates-for-paget-s-disease-of-bone-in-adults
#10
REVIEW
Luis Corral-Gudino, Adrian Jh Tan, Javier Del Pino-Montes, Stuart H Ralston
BACKGROUND: Bisphosphonates are considered to be the treatment of choice for people with Paget's disease of bone. However, the effects of bisphosphonates on patient-centred outcomes have not been extensively studied. There are insufficient data to determine whether reducing and maintaining biochemical markers of bone turnover to within the normal range improves quality of life and reduces the risk of complications. OBJECTIVES: To assess the benefits and harms of bisphosphonates for adult patients with Paget's disease of bone...
December 1, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29179892/update-on-osteoporosis-treatment
#11
REVIEW
Xavier Nogués, Daniel Martinez-Laguna
Treatment of osteoporosis should be directed primarily towards secondary prevention of fractures. The occurrence of drug-related adverse effects for the treatment of osteoporosis has led to a reevaluation of the indications, the duration of treatment and even withdrawal of some drugs from the market. This review has been made from different patient profiles that practitioners will find in usual practice; from patients with hip fracture with cognitive impairment, limitation of their day-to-day living activities and comorbidities, to active patients without any limitations; patients with vertebral fractures and non-vertebral fractures where secondary prevention is highly important...
November 24, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/29129436/effects-of-teriparatide-and-risedronate-on-new-fractures-in-post-menopausal-women-with-severe-osteoporosis-vero-a-multicentre-double-blind-double-dummy-randomised-controlled-trial
#12
David L Kendler, Fernando Marin, Cristiano A F Zerbini, Luis A Russo, Susan L Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Péter Lakatos, Astrid Fahrleitner-Pammer, Eric Lespessailles, Salvatore Minisola, Jean Jacques Body, Piet Geusens, Rüdiger Möricke, Pedro López-Romero
BACKGROUND: No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis. METHODS: In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1·50. Participants were randomly assigned to receive 20 μg of teriparatide once daily plus oral weekly placebo or 35 mg of oral risedronate once weekly plus daily injections of placebo for 24 months...
November 9, 2017: Lancet
https://www.readbyqxmd.com/read/29094069/third-generation-bisphosphonates-for-cochlear-otosclerosis-stabilizes-sensorineural-hearing-loss-in-long-term-follow-up
#13
Taha A Jan, Aaron K Remenschneider, Christopher Halpin, Margaret Seton, Michael J McKenna, Alicia M Quesnel
Objective: To assess long-term hearing outcomes in patients treated with third-generation bisphosphonates for otosclerosis-related progressive sensorineural hearing loss (SNHL). Study Design: Retrospective case series review. Methods: We performed a retrospective case series review of patients with otosclerosis and progressive SNHL. Patients were treated with either risedronate or zoledronate after a diagnosis of otosclerosis with a significant SNHL component...
October 2017: Laryngoscope Investigative Otolaryngology
https://www.readbyqxmd.com/read/29088987/effect-of-locally-administered-novel-biodegradable-chitosan-based-risedronate-zinc-hydroxyapatite-intra-pocket-dental-film-on-alveolar-bone-density-in-rat-model-of-periodontitis
#14
Deepak Kumar Khajuria, Saadath Fathima Zahra, Rema Razdan
The aim of this study was to develop a chitosan-based risedronate/zinc-hydroxyapatite intrapocket dental film (CRZHDF) for applications in the treatment of alveolar bone loss in an animal model of periodontitis. The physical characteristics (folding endurance, pH, mucoadhesive strength, risedronate content and release) of CRZHDF, exhibited results within the limit. X-ray diffraction analysis indicates reduced or disappeared crystallinity of risedronate and zinc-hydroxyapatite in presence of chitosan. Further, FTIR studies revealed stability of CRZHDF and compatibility between risedronate, zinc-hydroxyapatite and chitosan...
October 31, 2017: Journal of Biomaterials Science. Polymer Edition
https://www.readbyqxmd.com/read/29083977/examining-the-effect-of-medication-adherence-on-risk-of-subsequent-fracture-among-women-with-a-fragility-fracture-in-the-u-s-medicare-population
#15
Allison Keshishian, Natalie Boytsov, Russel Burge, Kelly Krohn, Louise Lombard, Xiang Zhang, Lin Xie, Onur Baser
BACKGROUND: In the United States, osteoporosis affects approximately 10 million people, of whom 80% are women, and it contributes a significant clinical burden to the community. Poor adherence to osteoporosis medications adds to the overall burden of illness. OBJECTIVE: To examine the association of osteoporosis medication adherence and the risk of a subsequent fracture among Medicare-enrolled women with a previous fragility fracture. METHODS: This study was a retrospective observational analysis of U...
November 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29068496/effectiveness-of-oral-bisphosphonates-in-reducing-fracture-risk-among-oral-glucocorticoid-users-three-matched-cohort-analyses
#16
M Amine Amiche, Linda E Lévesque, Tara Gomes, Jonathan D Adachi, Suzanne M Cadarette
The benefit of oral bisphosphonates in reducing fracture risk in glucocorticoid-induced osteoporosis is controversial. We aimed to estimate the effectiveness of oral bisphosphonates in reducing fracture risk in a cohort of new chronic oral glucocorticoid users. We created three matched cohorts using health care administrative data from Ontario, Canada. We included residents aged 66 years and older initiating chronic oral glucocorticoids (≥450 mg prednisone equivalent and ≥2 glucocorticoid prescriptions within a 6-month window) between January 1998 and September 2014...
October 25, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29063697/erythema-multiforme-like-eruption-induced-by-risedronate
#17
Leonardo Bianchi, Katharina Hansel, Paolo Romita, Caterina Foti, Luca Stingeni
No abstract text is available yet for this article.
November 2017: Contact Dermatitis
https://www.readbyqxmd.com/read/29045447/protective-effect-of-low-dose-risedronate-against-osteocyte-apoptosis-and-bone-loss-in-ovariectomized-rats
#18
Tingjun Ye, Peng Cao, Jin Qi, Qi Zhou, D Sudhaker Rao, Shijing Qiu
Osteocyte apoptosis is the first reaction to estrogen depletion, thereby stimulating osteoclastic bone resorption resulting in bone loss. We investigated the effects of two different risedronate (RIS) doses (high and low) on osteocyte apoptosis, osteoclast activity and bone loss in ovariectomized rats. Forty rats with ovariectomy (OVX) and sham ovariectomy (SHAM) were divided into 4 groups: 1) SHAM rats treated with saline (SHAM); 2) OVX rats treated with saline (OVX); 3) OVX rats treated with low-dose RIS (OVX-LR, 0...
2017: PloS One
https://www.readbyqxmd.com/read/29036218/crystallographic-and-thermodynamic-characterization-of-phenylaminopyridine-bisphosphonates-binding-to-human-farnesyl-pyrophosphate-synthase
#19
Jaeok Park, Dmitry Rodionov, Joris W De Schutter, Yih-Shyan Lin, Youla S Tsantrizos, Albert M Berghuis
Human farnesyl pyrophosphate synthase (hFPPS) catalyzes the production of the 15-carbon isoprenoid farnesyl pyrophosphate. The enzyme is a key regulator of the mevalonate pathway and a well-established drug target. Notably, it was elucidated as the molecular target of nitrogen-containing bisphosphonates, a class of drugs that have been widely successful against bone resorption disorders. More recently, research has focused on the anticancer effects of these inhibitors. In order to achieve increased non-skeletal tissue exposure, we created phenylaminopyridine bisphosphonates (PNP-BPs) that have bulky hydrophobic side chains through a structure-based approach...
2017: PloS One
https://www.readbyqxmd.com/read/28992488/hydroxyapatite-functionalization-to-trigger-adsorption-and-release-of-risedronate
#20
Lucia Forte, Stéphanie Sarda, Christèle Combes, Fabien Brouillet, Massimo Gazzano, Olivier Marsan, Elisa Boanini, Adriana Bigi
Bisphosphonates are widely employed drugs for the treatment of pathologies characterized by excessive bone resorption, and display a great affinity for apatitic supports. In this work we investigate how hydroxyapatite functionalization can influence the processes of adsorption and release of a bisphosphonate, namely risedronate. To this aim, pure hydroxyapatite (HA), hydroxyapatite with a partial substitution of Zn to Ca (ZnHA) and poly-ethylenimine-functionalized hydroxyapatite (HAPEI) were submitted to interaction with risedronate solution...
September 28, 2017: Colloids and Surfaces. B, Biointerfaces
keyword
keyword
27345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"